title: Assessment of risk and prophylaxis for deep vein thrombosis and pulmonary embolism in medically ill patients during their early days of hospital stay at a tertiary care center in a developing country.
abstract: OBJECTIVE
  Deep vein thrombosis (DVT) and pulmonary thromboembolism (PE) are important causes of morbidity and mortality in medically ill patients. This study was done to assess risk factors and prophylaxis given for DVT and PE in newly admitted medically ill patients during the first two weeks of their hospital stay at a tertiary care center hospital in India.
  
  
  METHODS
  All patients within one week of their admission in intensive care unit (ICU) and wards were enrolled in the study after an informed written consent. Patients who had DVT prophylaxis within the past month or any contraindications for DVT prophylaxis were excluded. A structured proforma was designed and effective risk stratification for DVT was done. Patients were followed for up to two weeks to record any changes in the risk categories and document any signs of PE or DVT if present. Any prophylaxis given for DVT or PE was noted.
  
  
  RESULTS
  Seventy-five percent of patients had the highest risk for DVT and PE. Only 12.5% had DVT prophylaxis within the first two days of admission. Within two weeks of admission, 30.8% of patients were discharged, and 16.2% died. 72.6% of the patients still in the wards belonged to the highest risk category. Clinical signs and symptoms of DVT and PE were present in 25.8% and 9.8% of patients, respectively after the second week of admission. 86% of symptomatic patients belonged to the highest risk category initially and none of them received any prophylaxis. 21.6% of the highest risk category patients died within two weeks of their admission. A statistically significant correlation was found between mortality and risk score of the patients for DVT and between lack of prophylaxis and mortality (p < 0.05).
  
  
  CONCLUSIONS
  A significant risk for DVT and PE exists in medically ill patients, but only a small proportion of the patients are given prophylaxis. This study underlines the need to aggressively implement DVT risk stratification strategy in medical patients and provide prophylaxis unless contraindicated.
authors.affiliation: Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Ambarish
authors.initials: A
authors.lastname: Pandey
authors.forename: Nivedita
authors.initials: N
authors.lastname: Patni
authors.forename: Mansher
authors.initials: M
authors.lastname: Singh
authors.forename: Randeep
authors.initials: R
authors.lastname: Guleria
mesh_terms: D000328:Adult; D000368:Aged; D003906:Developing Countries / Q000706:statistics & numerical data; D004334:Drug Administration Schedule; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006297:Health Services Accessibility; D017052:Hospital Mortality; D006801:Humans; D007194:India / Q000453:epidemiology; D007297:Inpatients / Q000706:statistics & numerical data; D007362:Intensive Care Units; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D010351:Patient Discharge; D018579:Patient Selection; D011446:Prospective Studies; D011655:Pulmonary Embolism / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*
chemical_list: D005343:Fibrinolytic Agents
references.citation: Thromb Res. 2007;119(2):145-55
references.pmid: 16516275
references.citation: Haematologica. 2005 May;90(5):678-84
references.pmid: 15921383
references.citation: J Thromb Haemost. 2004 Feb;2(2):221-7
references.pmid: 14995982
references.citation: Ann Intern Med. 2007 Feb 20;146(4):278-88
references.pmid: 17310052
references.citation: Eur J Vasc Endovasc Surg. 2009 Apr;37(4):482-5
references.pmid: 19208449
references.citation: Pol Arch Med Wewn. 2008 Apr;118(4):209-15
references.pmid: 18575420
references.citation: J Thromb Haemost. 2004 Nov;2(11):1892-8
references.pmid: 15550017
references.citation: J Indian Med Assoc. 2007 Sep;105(9):536, 538, 540 passim
references.pmid: 18338482
references.citation: J Manag Care Pharm. 2005 Nov-Dec;11(9):755-62
references.pmid: 16300419
references.citation: J Intern Med. 2004 Oct;256(4):338-48
references.pmid: 15367177
references.citation: Arch Intern Med. 2001 May 28;161(10):1268-79
references.pmid: 11371254
references.citation: Chest. 2004 Sep;126(3 Suppl):338S-400S
references.pmid: 15383478
references.citation: J Thromb Haemost. 2006 Jun;4(6):1266-70
references.pmid: 16706970
references.citation: Clin Ther. 2007 Nov;29(11):2395-405
references.pmid: 18158080
references.citation: Am J Hematol. 2005 Mar;78(3):167-72
references.pmid: 15726600
references.citation: Am J Cardiol. 2004 Jan 15;93(2):259-62
references.pmid: 14715365
references.citation: N Engl J Med. 2005 Mar 10;352(10):969-77
references.pmid: 15758007
references.citation: Recenti Prog Med. 2002 Feb;93(2):80-91
references.pmid: 11887350
references.citation: Semin Hematol. 2001 Apr;38(2 Suppl 5):12-9
references.pmid: 11449339
references.citation: J Clin Pathol. 2004 Dec;57(12):1254-7
references.pmid: 15563663